| **NCTID** | **Acronym** | **Clinical setting** | **Line of therapy** | **Treatment comparison** |
| --- | --- | --- | --- | --- |
| **Non-small cell lung cancer** | | | | |
| NCT02296125 | FLAURA | Advanced/metastatic EGFRm+ | 1L | osimertinib versus erlotinib or gefitinib |
| NCT01673867 | CheckMate017/057 | Metastatic squamous/non-squamous | 2L | nivolumab versus docetaxel |
| NCT03215706 | CheckMate9LA | Metastatic | 1L | nivolumab, ipilimumab, chemotherapy versus chemotherapy alone |
| **Breast cancer** | | | | |
| NCT01740427 | PALOMA-2 | Advanced postmenopausal ER-positive and HER2-negative | 1L | palbociclib, letrozole versus letrozole |
| NCT02819518 | KEYNOTE-355 | Locally recurrent inoperable or metastatic triple negative | 1L | pembrolizumab, chemotherapy vs. placebo, chemotherapy |
| NCT01772472 | KATHERINE | HER2-positive | Adjuvant | trastuzumab emtansine versus trastuzumab |
| **Colorectal cancer** | | | | |
| NCT04737187 | SUNLIGHT | Refractory metastatic | 3L | trifluridine, tipiracil, bevacizumab versus trifluridine, tipiracil |
| NCT01374425 | MAVERICC | Metastatic | 1L | bevacizumab, mFOLFOX6 versus bevacizumab, FOLFIRI |
| NCT02563002 | KEYNOTE-177 | Metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) | 2L+ | pembrolizumab versus standard of care |
| **Multiple Myeloma** | | | | |
| NCT01568866 | ENDEAVOR | Relapsing or progressing disease | 2L/3L | carfilzomib, dexamethasone versus bortezomib, dexamethasone |
| NCT02252172 | MAIA | Newly diagnosed | 1L | daratumumab, lenalidomide, dexamethasone versus lenalidomide, dexamethasone |
| NCT01239797 | ELOQUENT - 2 | Relapsed or refractory | 2L+ | elotuzumab, lenalidomide, dexamethasone versus lenalidomide, dexamethasone |